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Abstract : 
Epithelioid angiomyolipoma (eAML) is a rare renal neoplasm, in which the proportion of epithelioid cells in 
eAML accounts for more than 80% of the entire lesion. eAML often occurs with tuberous sclerosis complex 
as well as a sporadic manner. Histologically, the tumor predominantly consists of epithelioid cells with 
eosinophilic to clear cytoplasm, frequently showing pleomorphic ganglion-like or multinucleated giant 
cells. Spindle cells or adipose tissue also proliferate. Perivascular hyalinization and entrapped tubules are 
frequently identified. Immunohistochemically, neoplastic cells usually show the positivity for melanoma-
related antigen (HMB45, HMB50, CD63, and Melan A), and alpha-smooth muscle actin. Ultrastructurally, 
epithelioid cells contain striated, rhomboid, spherical or elliptical granules which may mimic melanosome, 
renin granules or rarely form typical premelanosomes. Approximately 40 % of cases with eAML behaves 
aggressively. As the investigation on indicators of clinical behavior is not enough to date, the accumulation 
and further examination of cases with eAML is required in the near future.
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INTRODUCTION
Renal angiomyolipoma (AML) is composed of 
various proportions of thick-walled blood vessels, 
smooth muscle and adipose tissue.1-4 This lesion has 
been for a long time considered to be a hamartoma, 
but is now regarded as a tumor.5,6 Eble et al. has 
propose the entity of renal epithelioid AML (eAML) 
which predominantly consists of epithelioid smooth 
muscle cells.7 However, the ratio of epithelioid cells 
in eAML varies from 10% to 100%, depending on 
the definition of reported papers.7-15 The biological 
behavior of eAML is also quite variable.7-15 In this 
article, we review eAML with focus on clinical and 
pathological aspects. 
DEFINITION
According to the recent World Health Organization 
Classification, eAML is a rare variant of AML and 
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the ratio of epithelioid cells in eAML is defined as 
more than 80% of total neoplasm.16
EPIDEMIOLOGY
eAML is often associated with tuberous sclerosis 
complex, but may occur also in sporadic fashion.4,7,8 
eAML accounts for 4.6% of all AMLs.12
CLINICAL SYMPTOMS
Patients generally present with pain, hematuria, 
mass and fever. Some tumors are incidentally 
found.1 In cases of association with tuberous 
sclerosis complex (TSC), symptoms are caused 
by involvements of organs other than the kidney 
(seizure due to cortical tuber, dyspnea due 
to pulmonary lymphangiomyomatosis, facial 
angiofibroma and mental retardation).
IMAGING FINDINGS
The contrast computed tomography (CT) 
scan examination of eAML generally reveals a 
solid hypervascular tumor with homogenous or 
heterogenous enhancement.17 The predominant 
enhancing pattern is rapid wash-in to slow wash-
out.17
PATHOLOGICAL FINDINGS
MACROSCOPIC FINDINGS
The tumor shows well-demarcated and solid 
mass. The cut surface of the tumor shows tan, 
grey or pink color with occasional hemorrhage or 
necrosis. 7, 18
MICROSCOPIC FINDINGS
The tumor predominantly consists of epithelioid 
cells (Fig.1a).  Pleomorphic ganglion-like or 
multinucleated giant cells are frequently observed 
(Fig. 1b).4,12 In some cases, spindle cells or adipose 
tissue proliferate.10,12 Perivascular hyalinization 
is often noted (Fig.1c).12 Entrapped tubules are 
frequently identified. 4,9 Mitotic activity is variable. 
4,9 Atypical mitoses may be seen in some cases 
(Fig.1d). 4,9 Necrosis is observed in a half of cases.4,9,10 
Tumor thrombus formation may be present in some 
cases.13 Melanin deposition may be observed in 
some cases.19,20 Sclerosing change is occasionally 
seen.10,21 eAML with extensive rhabdoid features 
is also reported.21 Oncocytoma-like eAML has 
been described.15 Conventional AMLs, including 
capsuloma may be observed in the nonneoplastic 
renal parenchyma and the contralateral kidney. 
Composite renal cell carcinoma may be rarely 
seen.22,23
IMMUNOHISTOCHEMICAL FINDINGS
Immunohistochemically, tumor cells are usually 
positive for Melanoma-related antigen (HMB45, 
HMB50 and CD63)(Fig.2a), Melan A, muscle specific 
actin and alpha-smooth muscle actin (Fig.2b).24-28 
Tyrosinase or epithelial markers including epithelial 
membrane antigen (EMA), low and high molecular 
weight cytokeratins are generally negative in most 
cases.24-28 E-cadherin show the frequent positivity.29 
Bcl-2, estrogen and progesterone receptors, 
placental alkaline phosphatase, c-kit and CD68 may 
be positive in some cases.28 The Ki-67 labeling index 
is generally less than 10%, but may exceed 10% in 
some cases.30 Strong nuclear positivity for p53 may 
be observed in some cases.30
UITRASTRUCTURAL FINDINGS
Epithelioid cells contain striated, rhomboid, 
spherical or elliptical granules. These granules may 
mimic melanosome, renin granules. The presence 
of needle- and rod-like crystalloid has been reported 
in epithelioid smooth muscle cells.2
MOLECULAR GENETIC FINDINGS
The allelic loss of chromosome 16p13.3 haboring 
TSC2 gene region and/or germ-line mutation of 
TSC1 or TSC2 are observed in eAML with tuberous 
31高知赤十字病院医学雑誌　第 2 4 巻　第 1 号　2 0 1 9 年
translocation-associated RCC (Xp11.2 RCC) and 
RCC associated with t(6;11) (t(6;11) RCC) is very 
important. In clear cell RCC, the tumor consists 
of clear cells with abundant glycogen and lipids, 
showing alveolar or acinar growth pattern. Thin-
walled blood vessels regularly proliferate among 
neoplastic cells.34,36 In TSC, it is no so easy for 
pathologists to distinguish clear cell RCC from 
eAML. If AML looks like clear cell RCC, it could be 
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sclerosis complex33 Loss of heterozygosity of TSC2 
gene is also identified in sporadic eAML.25,33 The 
mutation of the p53  gene was identified in one 
case.30 The TFE3 gene fusions may be observed in 
some cases.31,32 
DIFFERENTIAL DIAGNOSIS
The distinction from clear cell RCC, Xp11.2 
FIG 1. Histological findings. (A) The tumor is composed of epithelioid cells. (B) Multinucleated 
giant cells are observed. (C) Perivascular hyalinization is observed. (D). Atypical mitotic figure is 
seen.
FIG 2. Immunohistochemical findings. Neoplastic cells demonstrate the positivity for Melanosome-
related antigen (HMB45) (A) and alpha smooth muscle actin (B). 
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an eAML. In Xp11.2 RCC, the tumor is composed 
of mixed clear and eosinophilic cells with frequent 
voluminous cytoplasm. Psammoma bodies or 
hyaline nodules are often observed in the stroma.36 
Besides the most commonly seen morphology, 
Xp11.2 RCCs can be arranged in mostly solid 
pattern and composed of cells resembling urothelial 
ca, other can produce subnucleolar vacuoles (TFE3-
NONO) or quite recently, cases with predominantly 
clear cel l  population were associated with 
pseudorosette formation. Neoplastic cells of t(6;11) 
RCC are composed of tumor cells of two different 
sizes, namely larger and smaller cells, and basement 
membrane materials are surrounded by the latters, 
resulting in pseudorosettes formation.37
THERAPY
Radical  or partial  nephrectomy has been 
previously performed in most cases. Arteriographic 
embolization may be a feasible therapeutic option.38 
In tumors with metastatic disease, chemotherapy 
including doxorubicin or cisplatin, immunotherapy 
such as interferon, radiotherapy or molecular 
targeted therapy (sunitinib, sorafenib, axitinib, 
everolimus) were tried.25,38,39,44 Considering loss of 
function TSC1 and/or TSC2-encoding proteins 
(hamartin and/or tuberin, respectively) suppressing 
the mTOR pathway, inhibitors of mTOR pathway 
are hopeful for unresectable diseases.
PROGNOSIS
Approximately 40 % of  cases with eAML 
behaves in an aggressive fashion.33,37-45 Nese et 
al. investigated the clinicopathologic parameters 
that may be associated with disease progression, 
which include tuberous sclerosis complex or 
concomitant AML, necrosis, tumor size>7cm, 
extrarenal extention and/or renal vein involvement 
and carcinoma-like growth pattern. According to 
this report, the biological behavior was divided 
into three categories, namely low, intermediate, 
and high risk for disease progression which met 
zero to one, or two to three, or four to five adverse 
prognostic parameters, respectively. The low, 
intermediate and high risk categories showed the 
disease progression in 15%, 65% and 100% of all 
cases, respectively.10 Lei et al. indicated that a close 
follow-up is necessary for cases having 1) tumor 
size>9cm, 2) tumor thrombus formation in the vein, 
3) epithelioid cells >70% or atypical cells >60%, or 4) 
necrosis.13
FUTURE PERSPECTIVES
There are few reports on the clinical and 
pathological difference between eAML with and 
without TFE3 gene arrangement.32 Therefore, to 
elucidate the difference between these diseases 
is very important. Furthermore, to clarify the 
clinical indicators in eAML is also crucial. As the 
investigation on indicators of clinical behavior is 
not enough to date, the accumulation and further 
examination of cases with eAML is required in the 
near future.
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